文献速递免疫规划妇幼与学校卫生

提升产前Tdap疫苗接种率的质量改进项目

Increasing antepartum Tdap vaccine administration: A quality improvement initiative.
PubMed 文献 · Vaccine · 2019-05-20

为提升产前Tdap疫苗接种率,研究者基于产科医生调查识别障碍,制定5步干预措施,并通过15个月前后对照的月度病历审计评估效果。结果显示接种率从干预前的56.9%(362/636)升至干预后的64.5%(457/708),绝对差异7.6%(p<0.01),相对增幅13.4%。

要点

  • 多学科质量改进干预使产前Tdap接种率绝对提高7.6%。
  • 主要障碍包括员工培训不足、现场无疫苗和成本问题。
  • 干预包括教育、增加疫苗可及性、提醒医嘱、鼓励提供和文档转移。

核心结论

  • 质量改进干预使符合条件孕妇的产前Tdap接种率从56.9%升至64.5%,差异有统计学意义(p<0.01)。

研究设计与样本

  • 基于产科医生调查识别障碍,制定5步干预,采用15个月干预前后月度病历审计和两阶段控制图进行质量改进评估。

主要发现

  • 干预前636名符合条件孕妇中362名(56.9%)接种Tdap,干预后708名中457名(64.5%)接种。
  • 绝对差异7.6%(64.5% vs. 56.9%,p<0.01),相对增加13.4%。
  • 最常见障碍为员工培训有限、现场缺乏疫苗和成本。

关键数值与推荐

  • CDC推荐每次妊娠均接种产前Tdap疫苗以保护孕妇和婴儿。
  • 干预后接种率64.5%,干预前56.9%,绝对差异7.6%(p<0.01)。

临床怎么用

  • 可借鉴5步干预(教育、增加疫苗可及性、提醒 Standing order、鼓励提供、文档转移)提升产前Tdap接种率。

局限性

  • 需进一步研究产科障碍和孕妇拒绝接种的原因。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Centers for Disease Control and Prevention (CDC) recommends antepartum Tdap vaccination for women with each pregnancy to protect themselves and their vulnerable infants through transplacental transfer of maternal antibodies. Our aim was to increase the rate of antepartum Tdap vaccine administration by 20%. Obstetricians were surveyed to identify their present approaches and barriers to antepartum Tdap vaccine administration to help guide the development of our intervention. Limited staff training, lack of vaccine on site, and cost were the most commonly identified barriers. Using these survey responses, existing literature, and brainstorming conversations with colleagues, an interdisciplinary workgroup then created a fishbone analysis and developed a 5-step intervention to address these barriers: (1) educate providers and patients on Tdap and pertussis; (2) increase Tdap availability to all pregnant women; (3) remind staff of the established Tdap standing order to facilitate administration; (4) encourage obstetricians to offer Tdap; (5) transfer documentation of Tdap administration from office to hospital. To monitor changes in the process over 15 months of pre- and post-intervention, data were collected from monthly chart audits and a two-phase control chart was created. The main outcome measure was proportion of eligible women who received Tdap during current pregnancy. In the pre-intervention period, 362 of 636 eligible women (56.9%) received Tdap during their current pregnancy; in the post-intervention period, 457 of 708 eligible women (64.5%) received Tdap during their current pregnancy. This absolute difference of 7.6% (64.5% vs. 56.9%, p < 0.01) represents a 13.4% relative increase (64.5%/56.9%) in the proportion of clinically eligible pregnant women who received Tdap. This represents a clinically and statistically significant increase in the rate of antepartum Tdap immunization. More research is needed to further understand obstetric barriers and maternal refusal of antepartum Tdap administration.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Jina A, Wang TL, Seyferth ER, et al. Increasing antepartum Tdap vaccine administration: A quality improvement initiative. Vaccine. 2019. PMID: 31122862. doi:10.1016/j.vaccine.2019.05.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。